Platinum-Etoposide Chemotherapy in Elderly Patients With Small-Cell Lung Cancer: Results of a Randomized Multicenter Phase II Study Assessing Attenuated-Dose or Full-Dose With Lenograstim Prophylaxis—A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) Study
- 20 January 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (3) , 569-575
- https://doi.org/10.1200/jco.2005.11.140
Abstract
Purpose: Small-cell lung cancer (SCLC) is increasingly diagnosed in elderly patients, who are at higher risk of treatment-related morbidity and mortality. We conducted a randomized two-stage phase II study to assess the therapeutic index of two different platinum/etoposide regimens, attenuated-dose (AD) and full-dose (FD) plus prophylactic lenograstim. Patients and Methods: SCLC patients older than 70 years were randomized to receive four courses of cisplatin 25 mg/m2 on days 1 and 2, and etoposide 60 mg/m2 on days 1, 2, and 3 every 3 weeks (AD); or cisplatin 40 mg/m2 on days 1 and 2, and etoposide 100 mg/m2 on days 1, 2, and 3 every 3 weeks, plus lenograstim 5 mg/kg days 5 through 12, every 3 weeks (FD). A combined primary end point named therapeutic success (TS), which took into account activity, toxicity, and compliance, was used. Results: Ninety-five patients were enrolled. Seventy-five percent and 72% of the patients in the AD and FD arms, respectively, completed the treatment as per protocol. Response rate was 39% and 69% in the AD and FD arms, respectively, and 1-year survival probability was 18% and 39%, respectively. Treatment was well tolerated in both groups, with no grade 3 to 4 myelotoxicity in the AD arm, and 12% myelotoxicity in the FD arm. Overall, the observed TSs were 10 (36%) of 28 patients and 42 (63%) of 67 patients for AD and FD treatments, respectively. Conclusion: In elderly patients with SCLC a full-dose cisplatin/etoposide regimen combined with prophylactic lenograstim is active and feasible, while attenuated doses of the same regimen are associated with a poor therapeutic outcome.Keywords
This publication has 18 references indexed in Scilit:
- Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancerLung Cancer, 2004
- Management of small-cell lung cancer in the elderlyCritical Reviews in Oncology/Hematology, 2002
- Lung cancer: Update on the treatment of small cell lung cancer (SCLC)Annals of Oncology, 2000
- Five-Day Oral Etoposide2 Treatment for Advanced Small-Cell Lung Cancer: Randomized Comparison With Intravenous ChemotherapyJNCI Journal of the National Cancer Institute, 1997
- Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trialThe Lancet, 1996
- Treatment of Small Cell Lung Cancer in the ElderlyJournal of the American Geriatrics Society, 1994
- A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factorsBritish Journal of Cancer, 1993
- Predicting septic complications of chemotherapy: An analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsisEuropean Journal Of Cancer, 1993
- Retrospective review of chemotherapy for small cell lung cancer in the elderly: Does the end justify the means?European Journal of Cancer and Clinical Oncology, 1991
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989